novartis glp-1 glp 1 GlaxoSmithKline Recalls Antihypertensive Drug Made at Novartis Facility Novo Nordisk asks FDA not

The findings demonstrated a significant reduction in all-cause mortality, with an odds ratio of 0.49 (95% CI [0.410.60]

They have been implicated in promoting neuroprotection, improving neurological structure and functions, attenuating apoptosis, mitigating oxidative stress, and modulating neuroinflammation [11,12,13]

Celebrity and public figure disclosures normalized conversations about prescription weight management

Many people find their optimal dose is not the maximum dose

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July